50% of DOAC Doses are Inappropriate in Older Adults? On The Role of Appropriate Dosing
Anticoagulation Forum shared on LinkedIn:
”Did you know? Up to 50% of DOAC doses are inappropriate in older adults—with underdosing being more common than overdosing.
Underdosing can actually increase the risk of stroke, systemic embolism, and cardiovascular hospitalizations, without reducing bleed risk.
This new resource, Clinical Considerations: Anticoagulation Use in Older Adults, provides practical guidance on:
- Dosing best practices
- Managing fall risk
- Addressing modifiable bleeding risk factors
- Choosing the right anticoagulant through individualized, shared decision-making
Read the full resource here.
Then, test your knowledge with our Show You Know Quiz and see how your clinical decision-making stacks up.
This resource was made possible through our collaboration with the American Pharmacists Association (APhA), with support from an educational grant by the Bristol Myers Squibb and Pfizer Alliance.
Special thanks to our expert content developers and reviewers: Christina Bookwalter PharmD, MS MEd, BCPS, BCACP, Stacey Kaplon, PharmD, BCACP, Katie Meyer, PharmD, BCPS, BCGP, Amanda McFee Winans, PharmD, BCPS, CACP.”
Stay informed on the latets in the field of anticoagulation with Hemostasis Today.
-
Sep 9, 2025, 05:53Noel Hiney Highlights the Value of Blood Donation and Community Support
-
Sep 8, 2025, 22:5650% of DOAC Doses are Inappropriate in Older Adults? On The Role of Appropriate Dosing
-
Sep 8, 2025, 07:48Andreas Zirlik Announces EAS Rare Lipid Disorders Course at 7th Cardio Summit Graz
-
Sep 8, 2025, 07:11Naveen Pemmaraju at SOHO 2025: Presenting Effects of Rusfertide for Polycythemia Vera on Behalf of VERIFY Colleagues
-
Sep 8, 2025, 06:54Indraneel Deshmukh Presenting Posters on Polycytemia Vera and More at SOHO 2025
-
Sep 8, 2025, 14:22GLP-1 Receptor Agonists and Cardiovascular Benefits․ Role of Clinical Features
-
Sep 8, 2025, 14:21Hamza A. Salim: CTA Collateral Impairment Score Enhances Stroke Prognosis Accuracy
-
Sep 8, 2025, 06:19Maria Abbattista: From Combined Hormonal Contraceptives to Cerebral Vein Thrombosis
-
Sep 8, 2025, 06:12David Smadja: Molecular Determinants of Thrombosis Recurrence Risk Across Venous Thromboembolism Subtypes
-
Sep 7, 2025, 17:19Tessa Jaspers and Colleagues on Current Evidence Not Supporting Routine Anti-Xa Monitoring in Use of LMWH
-
Sep 8, 2025, 14:24Von Willebrand Factor as a Therapeutic Target․ From Development to Clinical Application
-
Sep 8, 2025, 02:35Reza Shojaei on the Real Worth of Hemoglobin Oxygen Carriers – HBOCs
-
Sep 7, 2025, 14:16Mary Kiige: Biological Hemoglobin Oxygen Carrier as a Lifesaving Oxygen Bridge
-
Sep 7, 2025, 14:13Breakthrough in Blood: Cécile Denis and INSERM Team Develop Nanobody Therapy for Type 1 VWD
-
Sep 2, 2025, 13:53Cost-Effective Strategies to Reduce Anaemia Highlighted in The Lancet Haematology
-
Sep 9, 2025, 04:57World Thrombosis Day 2025: Louise Bannon Invites Donations and Partnerships
-
Sep 8, 2025, 15:10Michael Makris on WHO’s Essential Medicines List Update: A Win for the Global Haemophilia Community
-
Sep 8, 2025, 14:26European Haemophilia Consortium Marks World PT Day: Physiotherapy Empowers People with Bleeding Disorders
-
Sep 8, 2025, 07:03Omar Adwan Explains the Key Difference Between Serum and Plasma
-
Sep 8, 2025, 07:00French Reference Center for Hemophilia Presented at The 22nd Turkish Hemophilia Congress